General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-02 | 2024-03 | -0.17 | -0.03 | 0.14 | 82.35% |
2024-02-15 | 2023-12 | -0.18 | -0.19 | -0.01 | -5.56% |
2023-11-02 | 2023-09 | -0.17 | -0.09 | 0.08 | 47.06% |
2023-08-03 | 2023-06 | -0.2 | -0.08 | 0.12 | 60.00% |
2023-05-04 | 2023-03 | -0.24 | -0.18 | 0.06 | 25.00% |
2023-02-28 | 2022-12 | -0.26 | -0.18 | 0.08 | 30.77% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-21 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-08-06 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-07-05 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-05-02 | HC Wainwright & Co. | Upgrade | Buy | |
2023-02-22 | RBC Capital | Upgrade | Outperform | |
2023-01-03 | RBC Capital | Upgrade | Outperform |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-05-20 | BALAKRISHNAN BRINDA | Director | 17.52K | Sale |
2024-05-20 | BILLEN DANIEL | Director | 28.14K | Sale |
2024-03-05 | DONLEY MATTHEW MAXWELL | Officer | 584.07K | Sale |
2024-03-05 | GREENLEAF PETER S | Chief Executive Officer | 1.52M | Sale |
2024-03-05 | HABIG SCOTT MICHAEL | Officer | 474.59K | Sale |
2024-05-20 | JAYNE DAVID ROLAND WALKER | Director | 44.36K | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Blackrock Inc. | 8.33M | 80.66M | 5.81% |
2023-06-29 | Armistice Capital, LLC | 4.69M | 45.42M | 3.27% |
2023-06-29 | NEA Management Company, LLC | 3.97M | 38.43M | 2.77% |
2023-06-29 | State Street Corporation | 2.63M | 25.48M | 1.84% |
2023-06-29 | Goldman Sachs Group Inc | 1.74M | 16.88M | 1.22% |
2023-06-29 | Morgan Stanley | 1.69M | 16.32M | 1.18% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-08-30 | iShares Russell 2000 ETF | 3.09M | 28.03M | 2.15% |
2023-07-30 | Fidelity Small Cap Index Fund | 1.21M | 13.98M | 0.84% |
2023-08-30 | iShares Russell 2000 Growth ETF | 1.13M | 10.28M | 0.79% |
2023-06-29 | College Retirement Equities Fund-Stock Account | 1.10M | 10.67M | 0.77% |
2023-08-30 | iShares NASDAQ Biotechnology ETF | 921.41K | 8.36M | 0.64% |
2023-07-30 | TIAA-CREF Funds-Quant Small Cap Equity Fund | 755.87K | 8.75M | 0.53% |
Shareholders will be ecstatic, with their stake up 30% over the past week following ObsEva SA‘s (NASDAQ:OBSV) latest quarterly results. Revenues came in 113% better than analyst models expected, at US$4.0kwhile statutory losses per share were US$0.48, in line with forecasts. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
Okkkkk @ryanKruse. U know!! what do U have a couple hundred shares?? Lol!. Stop acting like you KNOW SOMETHING ! Cause u don’t ! If it wasn’t for this over blown , media frenzy FLU, AUPH still would be $19-20. So just stop acting like u know something little man
@johnking.. you talk about approval soon then you say approval not happening. Then u speak of being bullish and then your Being bearish.. pretending ur selling at day highs and buying back at day lows.. ur a FAKE !!! stop acting like YOU KNOW SOMETHING..
John king, u are very confusing.. just last night ur saying FDA approval this Friday, then u go on to say this morning there isn’t going to be an FDA approval because they didn’t file an NDA, now this afternoon your telling people to sell before down trend .. very confused, stop acting like u know something
And how would you know
Iljin:suit filed form 13 D 5% ownership of auph ,= buyout in the works